Clinical information guide - lenvima.com
isit om/hcption. Time (months) Number of subjects at risk LENVIMA Placebo 0 2 4 6 8 10 12 14 16 18 20 22 24 26 261 225 198 176 159 148 136 92 66 44 24 11 3 0
Download Clinical information guide - lenvima.com
Information
Domain:
Source:
Link to this page:
Documents from same domain
HIGHLIGHTS OF PRESCRIBING INFORMATION - …
www.lenvima.comFULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 1.1 Differentiated Thyroid Cancer 1.2 Renal Cell Carcinoma 1.3 Hepatocellular Carcinoma
OR Eisai Assistance Program 1-866-61-EISAI …
www.lenvima.comIf signed by legal representative, describe the nature of his/her relationship with the patient: Name of Patient Name of Legal Representative Signature
HIGHLIGHTS OF PRESCRIBING INFORMATION
www.lenvima.comHepatocellular Carcinoma (HCC) • For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). (1.3) Endometrial Carcinoma (EC) • In combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma (EC) that is not microsatellite
Related documents
AVOCENT® AV 3000 SERIES KVM OVER IP SWITCHING …
42u.comAVOCENT® AV 3000 SERIES KVM OVER IP SWITCHING SOLUTIONS 1 Powerful User Access Control yyGrant access to specified users or implement LDAP directory authentication.
Ask the FDA and CMS/CLIA AABB 2016 Annual Meeting
www.aabb.orgAsk the FDA and CMS/CLIA . October 24, 2016 . AABB 2016 Annual Meeting . Orlando, FL . PANEL MEMBERS . ORIEJI ILLOH, MD, Acting Director, Division of Blood Components and Devices (DBCD),
School Council Meeting Minutes Wednesday 3 August 2016
www.coralparkps.vic.edu.au2 the new policy, for implementation for the 2017 school year. This Policy is in draft format and will be sent out prior to our next meeting. 2016 Parent Opinion Survey The 2016 Parent Opinion Survey will be conducted during Term 3 from 25 July to 5 August 2016.